Oral ferrous sulphate leads to a marked increase in pro-oxidant nontransferrin-bound iron - PubMed (original) (raw)

Oral ferrous sulphate leads to a marked increase in pro-oxidant nontransferrin-bound iron

C Hutchinson et al. Eur J Clin Invest. 2004 Nov.

No abstract available

PubMed Disclaimer

Similar articles

• Relationship of serum iron and nonprotein-bound iron concentrations following administration of ferrous sulfate in pigs.
  Chyka PA, Mandrell TD, Holley JE, Beegle BE. Chyka PA, et al. Vet Hum Toxicol. 1996 Feb;38(1):24-6. Vet Hum Toxicol. 1996. PMID: 8825744
• Effect of supplementation on iron status of geriatric subjects.
  Atukorala TM, Sheriff HR. Atukorala TM, et al. Ceylon Med J. 1986 Mar;31(1):15-20. Ceylon Med J. 1986. PMID: 3802304 No abstract available.
• Increase in Fe3+/Fe2+ ratio and iron-induced oxidative stress in Eales disease and presence of ferrous iron in circulating transferrin.
  Selvi R, Angayarkanni N, Bharathselvi M, Sivaramakrishna R, Anisha T, Jyotirmoy B, Vasanthi B. Selvi R, et al. Curr Eye Res. 2007 Jul-Aug;32(7-8):677-83. doi: 10.1080/02713680701486402. Curr Eye Res. 2007. PMID: 17852192
• The challenges of using serum ferritin to guide i.v. iron treatment practices in patients on hemodialysis with anemia.
  Easom A. Easom A. Nephrol Nurs J. 2006 Sep-Oct;33(5):543-51; quiz 552-3. Nephrol Nurs J. 2006. PMID: 17044438 Review.
• Iron deficiency: a concise review.
  Umbreit J. Umbreit J. Am J Hematol. 2005 Mar;78(3):225-31. doi: 10.1002/ajh.20249. Am J Hematol. 2005. PMID: 15726599 Review.

Cited by

• Iron requirements based upon iron absorption tests are poorly predicted by haematological indices in patients with inactive inflammatory bowel disease.
  Lomer MC, Cook WB, Jan-Mohamed HJ, Hutchinson C, Liu DY, Hider RC, Powell JJ. Lomer MC, et al. Br J Nutr. 2012 Jun;107(12):1806-11. doi: 10.1017/S0007114511004971. Epub 2011 Dec 9. Br J Nutr. 2012. PMID: 22152498 Free PMC article.
• Nanoparticulate iron(III) oxo-hydroxide delivers safe iron that is well absorbed and utilised in humans.
  Pereira DI, Bruggraber SF, Faria N, Poots LK, Tagmount MA, Aslam MF, Frazer DM, Vulpe CD, Anderson GJ, Powell JJ. Pereira DI, et al. Nanomedicine. 2014 Nov;10(8):1877-86. doi: 10.1016/j.nano.2014.06.012. Epub 2014 Jun 28. Nanomedicine. 2014. PMID: 24983890 Free PMC article.
• Daily Oral Supplementation with 60 mg of Elemental Iron for 12 Weeks Alters Blood Mitochondrial DNA Content, but Not Leukocyte Telomere Length in Cambodian Women.
  Steele SL, Hsieh AYY, Gadawski I, Kroeun H, Barr SI, Devlin AM, Côté HCF, Karakochuk CD. Steele SL, et al. Nutrients. 2021 May 31;13(6):1877. doi: 10.3390/nu13061877. Nutrients. 2021. PMID: 34072630 Free PMC article.
• The pharmacokinetics and pharmacodynamics of iron preparations.
  Geisser P, Burckhardt S. Geisser P, et al. Pharmaceutics. 2011 Jan 4;3(1):12-33. doi: 10.3390/pharmaceutics3010012. Pharmaceutics. 2011. PMID: 24310424 Free PMC article.
• Transfusion of human volunteers with older, stored red blood cells produces extravascular hemolysis and circulating non-transferrin-bound iron.
  Hod EA, Brittenham GM, Billote GB, Francis RO, Ginzburg YZ, Hendrickson JE, Jhang J, Schwartz J, Sharma S, Sheth S, Sireci AN, Stephens HL, Stotler BA, Wojczyk BS, Zimring JC, Spitalnik SL. Hod EA, et al. Blood. 2011 Dec 15;118(25):6675-82. doi: 10.1182/blood-2011-08-371849. Epub 2011 Oct 20. Blood. 2011. PMID: 22021369 Free PMC article. Clinical Trial.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Wiley

• Medical

  • MedlinePlus Health Information